Throughout the last four months, Moderna’s stock could grow by $51.00 – dramatic positive change that proves the COVID-19 lockdown did not affect the price. Most of the stocks fell in mid of March. Perhaps, its significant fight against the pandemic could affect the trust of the investors positively. Even though its Q1 2020 revenue fell by $505,000 million along with the operating income the demand for its stock has never fallen until today.
Q1 2020 total assets and total equity have risen significantly leaving behind negatively changed total liabilities. However, the total debt increased by over $5 million. Mid-term and long-term focused investors may enjoy MRNA since its weekly changes are very volatile.
CEO and Editor in Chief.
Living in the era of dynamic tech change Asan decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring Finance) writing for technology and as well as finance has been one of the precious aspects of his life